It seems reasonable to hypothesize that patients with low or very low expression of key ketolytic enzymes (e.g., OXCT1, BDH1) in their malignant gliomas may respond better to the KD therapy than those patients with positive expression of these enzymes. Here, BDH1 is linked to malignant glioma.